Tech Center 1600 • Art Units: 1624
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18567504 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | Non-Final OA | Katholieke Universiteit Leuven |
| 17431499 | USE OF SPIROPIDION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18934169 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17618118 | SWELL 1 MODULATORS FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, IMMUNE DEFICIENCIES, MALE INFERTILITY AND VASCULAR DISEASES | Final Rejection | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 17612989 | PHARMACEUTICAL COMBINATION | Final Rejection | Agency for Science, Technology and Research |
| 17593842 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Final Rejection | SK CHEMICALS CO., LTD. |
| 18556635 | Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. | Non-Final OA | UNIVERSIDAD TÉCNICA FEDERICO SANTA MARÍA |
| 18581095 | Halogenated Xanthenes as Vaccine Adjuvants | Final Rejection | UTI Limited Partnership |
| 18628470 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | Non-Final OA | PULMOKINE, INC. |
| 18600654 | Topical Antimicrobial Lotion for Treating Pyotraumatic Dermatitis Lesions | Final Rejection | Shear Kershman Laboratories, Inc. |
| 18103193 | Canine Melatonin-Containing Transmucosal Gel | Non-Final OA | Shear Kershman Laboratories, Inc. |
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | Non-Final OA | Nuvation Bio Inc, |
| 18575454 | NEW METHOD TO TREAT ACIDOSIS RELATED DISEASES WITH ACETOACETATE | Non-Final OA | CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS |
| 18567396 | SOLID STATE FORMS OF ABEXINOSTAT AND PROCESS FOR PREPARATION THEREOF | Non-Final OA | ASSIA CHEMICAL INDUSTRIES LTD. |
| 18038506 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | Non-Final OA | ASSIA CHEMICAL INDUSTRIES LTD. |
| 18567284 | T-TYPE CALCIUM CHANNEL BLOCKER | Non-Final OA | FUSO PHARMACEUTICAL INDUSTRIES, LTD. |
| 18528113 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENT | Non-Final OA | Oddity Labs, LLC |
| 18564553 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | Non-Final OA | Journey Colab Corp. |
| 18518796 | METHOD FOR PREPARING ACESULFAME POTASSIUM | Non-Final OA | ANHUI JIHNE INDUSTRIAL CO., LTD. |
| 18556300 | NEK7 INHIBITORS | Non-Final OA | Halia Therapeutics, Inc. |
| 17439584 | METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER USING KDM1A INHIBITORS SUCH AS THE COMPOUND VAFIDEMSTAT | Final Rejection | ORYZON GENOMICS, S.A. |
| 18258455 | 1,8-CINEOLE CONTAINING COMPOSITION FOR THERAPEUTIC USE | Non-Final OA | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH |
| 18333454 | CRYSTALLINE PPAR-DELTA AGONIST | Non-Final OA | Reneo Pharmaceuticals, Inc. |
| 18202051 | COMPOSITIONS FOR A DIETARY SUPPLEMENT TO MANAGE SENESCENT CELLS | Non-Final OA | Qualia Life Sciences LLC |
| 18038090 | BIOCIDE | Non-Final OA | PURGOS APS |
| 18033292 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Non-Final OA | GenEros Biopharma Ltd. |
| 17488120 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF LEFT-SIDED COLORECTAL CANCER | Non-Final OA | Isofol Medical AB |
| 18022081 | TOPICAL CANNABINOID COMPOSITIONS, ANTI-INFLAMMATORY CANNABINOID COMPOSITIONS, METHODS FOR FORMING, AND METHODS FOR TREATMENT | Non-Final OA | AGRONOMED MANAGEMENT, LLC |
| 18000586 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEAD LICE | Non-Final OA | CReDO Science, LLC |
| 17359714 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | Final Rejection | IMBRIA PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy